Earnings Preview: G1 Therapeutics (GTHX) Q1 Earnings Expected to DeclineZacks Investment Research • 04/27/22
G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022GlobeNewsWire • 04/21/22
G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/22
New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with ChemotherapyGlobeNewsWire • 03/31/22
G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 ConferenceGlobeNewsWire • 03/01/22
G1 Therapeutics' (GTHX) CEO Jack Bailey on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/23/22
G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational HighlightsGlobeNewsWire • 02/23/22
G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022GlobeNewsWire • 02/09/22
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor MicroenvironmentGlobeNewsWire • 12/01/21
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)GlobeNewsWire • 11/29/21
Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients' T Cell Immune Function When Administered Prior to ChemotherapyGlobeNewsWire • 11/12/21
G1 Therapeutics' (GTHX) CEO Jack Bailey on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational HighlightsGlobeNewsWire • 11/03/21
Earnings Preview: G1 Therapeutics (GTHX) Q3 Earnings Expected to DeclineZacks Investment Research • 10/27/21
G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021GlobeNewsWire • 10/20/21
Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to ChemotherapyGlobeNewsWire • 10/07/21
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid ServicesGlobeNewsWire • 10/01/21